Kornimate/medical-research-clean huggingface dataset:
janus kinase-stat inhibition to reduce apol1 associated kidney disease

Conditions: Chronic Kidney Diseases

Summary: the purpose of this study is to determine if the drug, baricitinib, is safe and effective in reducing high levels of albumin in the urine (albuminuria) in african american/blacks with apol1- associated focal segmental glomerulosclerosis (fsgs) and non-diabetic apol1-associated chronic kidney disease due to hypertension (htn-ckd).


Eligibility criteria:
inclusion criteria: * adults 18-70 years * high risk apol1 genotype (i.e., g1g1, g2g2, or g1g2) * fsgs diagnosed by kidney biopsy or clinically diagnosed htn-ckd * uacr ≥300 mg/dl * estimated glomerular filtration rate (egfr) ≥26 ml/min/1.73 m2 at screening * stable antihypertensive regimen for ≥ 1 month prior to enrolment * able to provide written informed consent exclusion criteria: * diabetes * hiv * sickle cell disease. * tip variant of fsgs. * systolic bp \>180 mmhg or diastolic bp \>90 mmhg based on average of 3 measurements. * active serious viral, bacterial, fungal or parasitic infection. * symptomatic herpes zoster infection within 12 weeks prior to study entry. * positive hepatitis b surface antigen during screening (could enroll after treatment). * previous kidney transplant. * history of chronic liver disease with the most recent available aspartate aminotransferase (ast) or alanine aminotransferase (alt) \>1.5 times the uln or the most recent available total bilirubin ≥1.5 times the uln * hemoglobin \<10 g/dl. * absolute lymphocyte count (alc)\<500cells/mm3 or absolute neutrophil count (anc) \< 1000 cells/mm3. * pregnant or nursing at time of enrollment * prior or current treatment with jak inhibitor. * current use of potent immunosuppressants such as abatacept, adalimumab, anakinra, azathioprine, certolizumab, etanercept, golimumab, infliximab, probenecid, rituximab, ruxolitinib, sarilumab, tofacitinib, or tocilizumab. * high dose corticosteroids (\>10 mg per day of prednisone or equivalent) or an unstable dosing regimen of corticosteroids within 2 weeks of study entry or within 6 weeks of planned randomization.

Keywords: apol1 focal segmental glomerulosclerosis (fsgs)
modafinil in the treatment of ptsd (posttraumatic stress disorder)

Conditions: Posttraumatic Stress Disorder

Summary: the purpose of this study is to determine if modafinil is more effective than placebo in the treatment of posttraumatic stress disorder (ptsd) in male combat veterans who have been deployed to iraq or afghanistan.

there is a high rate of posttraumatic stress disorder (ptsd) in soldiers exposed to combat in operations enduring freedom and iraqi freedom (oef/oif). unfortunately, currently available treatments for combat-related ptsd have produced modest treatment gains at best. new treatment strategies that can be directed toward objectively measured correlates of ptsd are urgently needed. specific aims: 1) to determine if there is evidence for the effectiveness and tolerability of adjunctive modafinil in the treatment of combat-related ptsd. we hypothesize that oef/oif veterans with ptsd randomized to modafinil 100mg/day for four weeks will experience more improvement in ptsd symptoms than oef/oif veterans with ptsd randomized to placebo treatment for four weeks. 2) to determine if ptsd symptom severity is associated with electrophysiological and neuropsychological measures of pre-attention and attention and if these measures change to a greater degree in participants randomized to modafinil versus those randomized to placebo. we hypothesize modafinil treatment will result in greater changes in electrophysiological and neuropsychological measures of pre-attention and attention than placebo treatment.

Eligibility criteria:
inclusion criteria: * oef/oif veteran with a history of deploying to afghanistan or iraq * right-handed * male 20-60 years of age * meets diagnostic and statistical manual (dsm-iv) diagnostic criteria for ptsd * competent to give informed consent * access to a telephone * stable psychotropic medication regimen for a minimum of four weeks prior to enrollment * able and willing to complete the required schedule of evaluations (baseline in person, 1 week by phone, 2 week in person, 4 week in person) exclusion criteria: * diagnosis of schizophrenia, schizoaffective disorder or bipolar disorder * current substance abuse or dependence * history of seizure disorder or severe traumatic brain injury * history of attempted suicide within the previous two years or active suicidal ideation within the past month * currently taking benzodiazepines except for bedtime dosing only * currently taking stimulant medication * known allergic reaction to modafinil or currently taking medication * that may have altered metabolism if taken with modafinil: tricyclic antidepressants (amitriptyline; nortriptyline; desipramine; imipramine; cns stimulants (amphetamine; d-ampthetamine; atomoxetine); carbamazepine; phenytoin; phenobarbitol; rifampin; ketaconazole; mao inhibitors (isoniazid; selegiline); warfarin; diazepam; mephenytoin; cyclosporine; theophylline

Keywords: modafinil p50 attentional bias
radioembolization for hepatocellular carcinoma with portal vein tumoral thrombosis

Conditions: Hepatocellular Carcinoma

Summary: in patients with hgepatocellular carcinoma (hcc) and portal vein tumoral thrombosis (pvtt), sorafenib represents the treatment of choice but more recently, trans-arterial radioembolization (tare) with yttrium-90 has been also proposed. a considerable percentage of such patients are not only able to achieve stability of the disease, but also to obtain a complete radiological response (cr). the possibility of achieving a cr might allow these patients to be listed for liver transplantation (lt), in order to cure not only the cancer but also the underlying cirrhosis that generated it.


Eligibility criteria:
inclusion criteria: 1. diagnosis of hcc; 2. age ≥ 18 years; 3. performance status according to eastern cooperative oncology group 0-1; 4. preserved liver function (child-pugh score ≤b7); 5. pvtt limited to the first order portal branch. exclusion criteria: 1. any contraindication to tare treatment; 2. macrovascular invasion extended to the main portal trunk and/or to the contralateral portal branch; 3. presence of extra-hepatic disease

Keywords: hepatocellular carcinoma macrovascular invasion portal vein thrombosis
the effect of mulligan's mobilization with movement versus dry needling on pain,function,and range of motion among athletes with hip adductor related groin pain and dysfunction

Conditions: Hip Adduction Strength; Groin Pain; Groin Injury

Summary: this study aims to highlight and investigate the effectiveness of two common management practices in physiotherapy, dry needling intervention as a soft tissue technique and mulligan mobilization with movements mwm as a joint technique, on pain, function, and range of motion among athletes with hip adductor-related groin pain and dysfunction.

background: injuries are considered a common challenge in the sports field, 31% of the injuries are muscular, especially in the lower extremities. injuries in the groin area are a major and serious problem because they are common, lead to prolonged symptoms, and had a high recurrence rate. study objective: this study aims to highlight and investigate the effectiveness of two common management practices in physiotherapy, dry needling dn intervention as a soft tissue technique and mulligan mobilization with movements mwm as a joint technique. methods: a convenience sampling of thirty football players who were diagnosed with hip adductor-related groin pain and dysfunction were recruited from different cities in the west bank who participated in this randomized clinical trial, the participants were randomly divided into two groups, the dry needling group (15), and dry needling combined with mulligan mobilization mwm (15). numiric pain rating scale (nprs), five-second copenhagen squeeze test, hip abduction range of motion, adductor squeeze test, flexion abduction external rotation test (faber), y balance test, and the copenhagen hip and groin outcome score (hagos) were used as outcome measures (nprs and 5-second squeeze test performed each session for the two groups).

Eligibility criteria:
inclusion criteria: 1. athletes suffered from unilateral adductor-related groin pain, grades 1 and 2. 2. acute, subacute, or chronic athletes with hip adductor-related groin pain and dysfunction. 3. groin pain during or after activities. 4. pain at palpation of the adductors and their origin. 5. pain on resistance against adduction. 6. aged 15- 35 years old. exclusion criteria: patients with other causes of groin pain such as: 1. lymphadenitis. 2. prostatitis, urinary infections, malignancy. 3. spinal pathology. 4. hip joint osteoarthritis. 5. inguinal-related or iliopsoas-related groin pain. 6. femoral or inguinal hernia. 7. referral pain and adductor strain grade 3. 8. current use of medication.

Keywords: athletes hip adductor groin pain athletes with groin pain athletes with hip dysfunction
urine sample processing study

Conditions: Acute Kidney Injury

Summary: the objective of the study is to collect and process urine samples from intensive care unit (icu) subjects with moderate to severe (stage 2 or 3) acute kidney injury (aki) for use in assessing the effects of urine sample freezing and various storage conditions on nephroclear™ ccl14 test results. this study is observational and will have no impact on the medical management of the subject.


Eligibility criteria:
inclusion criteria: 1. males and females 21 years of age or older; 2. receiving care in an intensive care unit; 3. expected to remain in the icu for at least 48 hours after enrollment; 4. use of indwelling urinary catheter as standard care at the time of enrollment; 5. subject must have acute kidney injury (kdigo stage 2 or stage 3) at the time of sample collection; 6. urine sample must be collected within 36 hours of meeting kdigo stage 2 criteria; 7. written informed consent provided by patient or legally authorized representative (lar). exclusion criteria: 1. prior kidney transplantation; 2. comfort-measures-only status; 3. already receiving dialysis (either acute or chronic) or in imminent need of dialysis at the time of enrollment; 4. known infection with human immunodeficiency virus (hiv) or active hepatitis (acute or chronic); 5. special populations, pregnant women, prisoners or institutionalized individuals.
shr1459 in combination with yy-20394 in recurrent and refractory b-cell non-hodgkin's lymphoma

Conditions: Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

Summary: the study is evaluating the efficacy, and safety of shr1459 combined with yy-20394 for recurrent and refractory b-cell non-hodgkin's lymphoma in adults.


Eligibility criteria:
inclusion criteria: 1. histologically confirmed diagnosis of b-cell nhl such as dlbcl, fl and mcl 2. patients received at least 2 lines of systemic therapy 3. previously received anti- cd20 treatment 4. patients in stage ii should also be unsuitable or unwilling to receive allogeneic hematopoietic stem cell transplantation 5. patients must have an acceptable organ function exclusion criteria: 1. previously treated with pi3k inhibitors or btk inhibitors 2. unresolved toxicity of ctcae grade \> 1 from prior anti-lymphoma therapy 3. chemotherapy or other investigational therapy within 28 days (or 5 times the half-life time, whichever is shorter) before starting cycle 1 4. significant concurrent medical disease or condition which according to the investigators' judgement 5. active hepatitis b, c or hiv infection 6. infection requiring treatment 2 weeks prior to the first dosing
a trial to study neladenoson bialanate over 20 weeks in patients with chronic heart failure with reduced ejection fraction

Conditions: Heart Failure

Summary: the objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (bay 1067197) when given in addition to standard therapy for heart failure with reduced ejection fraction (hfref).


Eligibility criteria:
inclusion criteria: * men or women aged 18 years and older * diagnosis of chronic heart failure (chf), nyha ( new york heart association ) class ii-iv, lvef ≤ 35% and elevated nt-probnp exclusion criteria: * acute de-novo heart failure * requirement of any intravenous (iv) treatments following 48 hours prior to randomization * mechanical support (e.g. intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device) * any cause of chronic heart failure other than ischemic cardiomyopathy and idiopathic dilated cardiomyopathy

Keywords: chronic heart failure heart failure with reduced ejection fraction
voriconazole as prophylaxis for liver transplant recipients

Conditions: Fungemia; Mycoses

Summary: the study aims to determine if voriconazole prevents invasive fungal infections in liver transplant recipients. endpoints would be: occurrence of invasive fungal infection and fungal colonization. two groups will be compared: patients who received voriconazole as prophylaxis and historical controls who did not receive this prophylaxis.

the following variables will be followed: time and location of positive cultures, underlying diseases and severity of illness, voriconazole usage prophylactically, physical exam findings, laboratory and radiographical data, antimicrobial usage, microbiological data and resistance patterns, choice of antifungal drugs once organism identified, suspected source of infection, microbiological outcomes, laboratory results, demographic information, medications, clinical outcome, gender, weight, ethnicity, and past medical history.

Eligibility criteria:
inclusion criteria: * patients receiving a liver transplant at university of pittsburgh medical center (upmc) between january 1, 2001 and june 30, 2005.

Keywords: liver transplant voriconazole prophylaxis liver transplantation voriconazole
building an evidence base for weight loss strategies among those with chronic sci-the glb-sci+

Conditions: Spinal Cord Injuries; Obesity; Weight Loss; Diet Modification

Summary: this study's overarching aim is to follow a systematic approach that incorporates community-based participatory research (cbpr) to develop a multi-component weight loss intervention that may yield significant effects for a chronic sci sample. the approach is to obtain data on the 3 unique strategies (prepackaged/portion-controlled meals; enhanced self-monitoring; the glb-sci) to inform design of an empirically supported and consumer-validated multicomponent intervention program, that combines the best of the 3 approaches into one unique intervention, the glb sci+. based on the investigators' prior experience with adapting and delivering the glb aim (a lifestyle intervention previously adapted for those with impaired mobility), interim findings, existing literature, and consumer feedback, they hypothesize that these 3 unique strategies may confer individualized benefits to people with sci given their complex disability-related barriers to weight loss.


Eligibility criteria:
inclusion criteria: * over 18 years old * have had a spinal cord injury for at least 1 year * overweight as evidenced by bmi \> 25 * must have sufficient upper arm mobility to engage in exercise * must have access to the internet * must be able to obtain physician signed clearance to participate in a weight management intervention exclusion criteria: * cognitive impairment which substantially impairs autonomy (e.g. mental retardation) * medical issues for which exercise is contraindicated such as uncontrolled hypertension or coronary heart disease, * pregnancy * not fluent in english * presence of grade 3 or 4 pressure ulcer * previously diagnosed eating disorder
eplerenone and aliskiren research targeting hypertensive patients with left ventricular hypertrophy

Conditions: Hypertensive Left Ventricular Hypertrophy

Summary: the primary objective of this study is to determine which treatment will be more effective to reduce left ventricular mass in hypertensive patients with left ventricular hypertrophy comparing aliskiren and eplerenone.


Eligibility criteria:
inclusion criteria: male or female ≧ 20 years of age clinical diagnosis of hypertension patients who are able to provide written informed consent exclusion criteria: 1. history of congestive heart failure, myocardial infarction, or coronary revascularization in the recent 6 months. 2. planned to taking percutaneous coronary intervention and coronary artery bypass graft 3. severe hypertension (≧ 180/110 mmhg) or secondary hypertension or malignant hypertension. 4. history of stroke, cerebral hemorrhage, subarachnoid hemorrhage, transient ischemic attack in the recent 6 months 5. severe valvular heart disease or atrial fibrillation 6. congenital heart disease 7. severe heart failure (nyha functional class ⅳ) 8. current treatment with aliskiren or eplerenone or diuretics 9. taking potassium preparation or potassium-sparing diuretic 10. estimated gfr ≦ 30ml/min/1.73m２ at screening or current treatment with hemodialysis 11. potassium \> 5.0meq/l at screening 12. diabetes mellitus with microalbuminuria or albuminuria 13. impairment of liver function (liver failure, liver cirrhosis) 14. pregnant woman or possibly pregnant woman 15. history of malignant tumor include hematological neoplasm 16. current treatment with itraconazole, cyclosporin, ritonavir or nelfinavir 17. prior treatment with, hypersensitivity to, intolerance of or contra-indication to aliskiren and/or eplerenone 18. current participation in another clinical trial 19. serious non-cardiovascular disease severely limiting life expectancy 20. contra-indication to mri

Keywords: hypertension left ventricular hypertrophy renin angiotensin system aldosterone aliskiren eplerenone p3np
psychological aspects and insulin pump therapy

Conditions: Type 1 Diabetes

Summary: the continuous subcutaneous insulin infusion (csii) might have an impact on psychological distress and some psychological factors might be predictors of metabolic control; however, very few studies conducted so far were specifically focused on the psychological aspects of csii therapy in adults affected by t1dm.

the aim of this project is to study the psychological effect of continuous subcutaneous insulin infusion (csii) in a cohort of type 1 diabetic patients and to explore the influence of psychological factors (coping style, locus of control, self-efficacy) on glycaemic control. a sample of 36 type 1 diabetic patients will be recruited at endocrinology, diabetes and metabolism division of verona city hospital. among t1dm patients routinely followed by our institution the study will be proposed to those starting the csii therapy based on the inclusion and exclusion criteria. each study participants will provide a written informed consent and will undergo a set of 4 psychological evaluation assessing depression, anxiety, self-efficacy, perceived interference caused by diabetes, family support, locus of control and coping strategies on top of routine medical examination and laboratory testing for outcome measures at baseline and after 6, 12 and 24 months after study entry.

Eligibility criteria:
inclusion criteria: * type 1 diabetes * transition to csii * age \>18 years exclusion criteria: * current schizophrenia/ psychotic disorders, bipolar disorders, addictive disorders, personality disorders * pregnancy
multimodal imaging evaluation and prognostic analysis of cardiac allograft vasculopathy in heart transplantation

Conditions: Heart Transplant

Summary: the aim is to (1) establish a system of multimodal imaging technology; (2) jointly apply multimodal imaging technology to diagnose of cardiac allograft vasculopathy of heart transplantation; (3) construct a multimodal imaging technology prediction model of adverse events, screening the best non-invasive imaging prediction indicators.

this study will enrolled 1000 ht patients, and the cardiac allograft vasculopathy will be evaluated by multimodal imaging technology. the aim is to (1) establish a system of multimodal imaging technology; (2) jointly apply multimodal imaging technology to diagnose of cardiac allograft vasculopathy of heart transplantation; (3) construct a multimodal imaging technology prediction model of adverse events, screening the best non-invasive imaging prediction indicators.

Eligibility criteria:
inclusion criteria: • heart transplantation after january 1st, 2015. exclusion criteria: •age \< 18 years at the time of transplantation; died within 48 h; heart-lung transplantation; heart/kidney transplantation; re-transplanted within 7 days after transplantation.
hot water irrigation in posterior epistaxis

Conditions: Epistaxis

Summary: this study was aimed to assess the efficacy and factors affecting the success of hot water irrigation in management of posterior epistaxis.

epistaxis has been reported to occur in up to 60% of general population.this condition has incidence peaks at ages younger than 10 years and older than 50 years. epistaxis appears to occur more in males than females . in rare cases massive nasal bleeding can lead to death. nasal bleeding usually responds to first aid measures such as compression.when epistaxis doesn't respond to simple measures. the source of bleeding should be located and treated appropriately. treatment options to be considered include topical vasoconstriction, chemical cautery, electrocautery, nasal packing, posterior gauze packing, use of balloon system, and arterial ligation or embolization. hospital admission should be considered with patients with comorbid conditions or complication of blood loss. nasal hot water irrigation was first described by guice in 1878 as an effective method of treating severe life-threatening epistaxis. however, the technique was already in use by nineteenth century obstetricians as a method of treating postpartum bleeding . in the second half of the twenties century, nasal packing products and the development of endoscopic sinus surgery almost completely replaced the irrigation technique as treatment for posterior epistaxis. however, stangerup et al. (1996) have demonstrated that hot water irrigation, using temperatures of up to 50°c, produces vasodilation and oedema of the nasal mucosa without the risk of necrosis and accelerating the clotting cascade. hot water irrigation had a higher success rate (55 %) in treating posterior epistaxis, compared with nasal packing (44 %) .using a modified irrigation technique, was able to stop bleeding permanently in up to 82 %of cases of posterior epistaxis, including patients receiving antiplatelet agents or anticoagulants . during a follow-up period of four to 24 months. furthermore, successful hot water irrigation was associated with less nasal trauma, significantly less pain, fewer surgical procedures and avoidance of a hospital stay.

Eligibility criteria:
inclusion criteria: * patients age: \> 10 years. * failed first aid measures. exclusion criteria: * patients age \< 10 years old. * patients with anterior epistaxis. * patients presented with hemorrhagic shock. * patients presented with post-surgical bleeding. * suspected nasal pathology e.g tumors or trauma.